Intel, Consensys Health Combine Blockchain And Ai For Clinical Trials Management

By Author: emrindustry
Total Articles: 266
Comment this article

“On the flip side, patients want to be involved in trials, but often can’t find the right ones,” said Sean T. Manion, chief scientific officer at New York City-based blockchain and machine learning vendor ConsenSys Health.

“Nearly 50% of cancer patients want to be involved in clinical trials, yet only 5% are able to do so,” he said. “This limited access to groundbreaking treatments and being part of the system of science to improve treatments for future patients is the other side of the problem.”

One of the major reasons clinical trial-matching and recruitment is so slow is that it’s largely limited by laws and regulations related to patient privacy.

PROPOSAL

“At ConsenSys Health, we are focused on a new way of approaching these concerns using a federated approach, where the data stays safely and privately at rest and only answers to questions about that data are shared,” said Manion. “This is made possible by the combination of three families of technology: blockchain, decentralized AI, and privacy-preserving software and hardware.

“We are working with Intel to align ...
... their next generation of Intel SGX hardware for confidential computing with our blockchain-orchestrated federated learning system, Elevated Compute, to solve a variety of problems in healthcare and life sciences.”

For clinical trial-matching, the ability to identify sites and individuals that might be good choices for a clinical trial is made possible through this approach, including a validated audit trail of the data via blockchain and privacy preservation with Intel SGX hardware.

This will enable faster and less-expensive trials, with more access and inclusion for patients, all resulting in a more robust advancement of new treatments and improved health outcomes, he noted.

“We were using Intel SGX hardware to simulate the privacy-preserving attributes for comparing to eligibility for patients for clinical trials, allowing deployed algorithms and analytics sent to the data to do the necessary analysis of the data in the trusted enclave the Intel SGX hardware creates, without ever moving and exposing the data,” he explained.

“This served to demonstrate the viability of this privacy preservation for future use in safely applying our blockchain-orchestrated federated learning solution to clinical trial-matching and other future-state use cases like data analysis for multisite trials without centralizing the data,” he added.

MEETING THE CHALLENGE

ConsenSys Health worked directly with the Intel SGX team using synthetic health data to run this proof of concept.

“We compared their latest version of Intel SGX in Ice Lake to their earlier version,” Manion said. “There has been a significant increase in the enclave size – the amount of data that can be processed at once – in the new version, allowing for faster and more data-processing in a privacy-preserving way. We also worked with a large pharmaceutical company to validate the problem area and solution design.”